In addition to the on-target, off-tumor effects of both CD19 and BCMA CAR-T causing B-cell/plasma cell aplasia and subsequent hypogammaglobulinemia [7], significant impairment in T-cell-mediated immunity occurs. The gene discussed is CD19; the disease is neoplasm.